PharmaCom BioVet, Inc. (PINKSHEETS: PHMB) is pleased to announce their corporate vision to research, treat and compassionately care for companion animals afflicted with cancer.

PharmaCom BioVet, Inc. is dedicated to advancing the medical care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The company's focus is on furthering cancer research, treatment and care for companion animals. Their primary goals include creating compassionate care facilities to treat animals afflicted with cancer and to find products in conjunction with procedures that will eradicate cancer in companion animals.

"Our ultimate goal is to work towards a day when we can eradicate cancer in companion animals as we utilize our personal and professional relationships to create a think tank of the brightest minds in the veterinary and university fields to advance research and technology, all while focusing on compassionate care," said Gary S. Berthold, Founder and CEO of PharmaCom BioVet.

With 75 million dogs in the United State alone, Americans spend $9.8 Billion a year on veterinary services. Cancer is the number one cause of death in dogs, with one out of every three dogs being diagnosed with cancer and 50% of those dogs will succumb to their illness.

In response to demand and the current lack of adequate cancer treatment options and facilities for animal lovers whose pets are suffering from cancer, PharmaCom BioVet intends to open a network of companion animal cancer care centers throughout North America.

About PharmaCom BioVet, Inc.:

PharmaCom BioVet, Inc. is dedicated to advancing the medical care industry for companion animals by establishing state-of-the-art treatment centers for lymphoma and other forms of cancer throughout the country. The purpose of these centers is to help prolong the quality of life for companion animals with cancer and pursue the potential for complete cure. These centers will also operate under the philosophy of providing a compassionate care environment for both companion animal patients and their owners. For more information, please visit our website www.PharmaComBioVet.com.

DISCLOSURE:

"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in PharmaCom BioVet, Inc.'s filings with the Securities and Exchange Commission. These risks could cause PharmaCom BioVet, Inc.'s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, PharmaCom BioVet, Inc.

Contact: Market Ideas, Inc. 877-295-3981 ext. 2 info@marketideasinc.com

PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
Von Apr 2024 bis Mai 2024 Click Here for more PharmaCom BioVet (CE) Charts.
PharmaCom BioVet (CE) (USOTC:PHMB)
Historical Stock Chart
Von Mai 2023 bis Mai 2024 Click Here for more PharmaCom BioVet (CE) Charts.